IDH1 and acute myeloid leukemia: The suggestion of dasatinib as IDH1 mutant-specific treatment is supported by data from Tavor et al. [45] revealing a significant enrichment of samples with IDH1 mutations (33.3%) versus IDH1-wt AML samples (14.3%) among those responding to dasatinib ex vivo (hypergeometric test, p = 0.022).